Drug-induced liver injury was reported in 1 asymptomatic patient in one of the once-daily danuglipron dose-optimization studies. Pfizer has made the decision to discontinue the clinical development ...

The study was unlikely to meet its primary endpoint based on overall efficacy and safety results from a pre-planned futility analysis. BeiGene has made the decision to end the clinical development ...

Over the past decade, industry-sponsored clinical trial activity at UAB has grown steadily. To sustain and accelerate this momentum, the Clinical Trialist Development Program (CTDP) supports promising ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...

Charitharth Vivek Lal, M.D. is program director of the Golden Week Program™, an evidence-based, standardized, quality improvement plan, established and implemented at the UAB Regional Neonatal ...

Genmab (GMAB) will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most ...

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics ...

As advancements in medical science progress, clinical research and development (R&D) are subject to more sophisticated and complex study designs and protocols that require precise global coordination ...

WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune disease, announced today that Mr. Tom Shea ...